medroxyprogesterone acetate has been researched along with Ulcer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baeten, JM; Chohan, BH; Hassan, W; Kreiss, JK; Lavreys, L; Mandaliya, K; Ndinya-Achola, JO; Overbaugh, J; Panteleeff, DD; Richardson, BA | 1 |
| Jackson, DJ; Kreiss, J; Lavreys, L; Mandaliya, K; Martin, HL; Ndinya-Achola, JO; Nyange, PM; Richardson, BA | 1 |
| Denny, L; Kuhn, L; Pollack, AE; Wright, TC | 1 |
3 other study(ies) available for medroxyprogesterone acetate and Ulcer
| Article | Year |
|---|---|
Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cohort Studies; Contraceptive Agents, Female; Female; Genital Diseases, Female; HIV-1; Humans; Injections; Medroxyprogesterone Acetate; Multivariate Analysis; Prospective Studies; RNA, Viral; Sexual Behavior; Ulcer; Viral Load | 2004 |
Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1.
Topics: Behavior; Candidiasis, Vulvovaginal; Contraception; Contraceptive Agents, Female; Contraceptive Devices; Demography; Female; HIV Seropositivity; HIV-1; Humans; Kenya; Medroxyprogesterone Acetate; Multivariate Analysis; Prospective Studies; Risk Factors; Sex Work; Sexually Transmitted Diseases; Ulcer; Vaginal Discharge; Vulvitis | 1998 |
Prevalence of visible disruption of cervical epithelium and cervical ectopy in African women using Depo-Provera.
Topics: Adult; Aged; Aging; Atrophy; Cervix Uteri; Contraceptive Agents, Female; Epithelium; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Odds Ratio; Parity; South Africa; Ulcer; Uterine Cervical Diseases; Uterine Cervicitis | 1999 |